Showing results (11-20 of 40) with videos related to
Sort By:
Pageof 4
Clinical Lymphoma, Myeloma & Leukemia|March 7, 2020
Defining Acute Myeloid Leukemia Ontogeny in Older PatientsMegan Melody, Andrew Kuykendall, David Sallman, et al.Clinical Lymphoma, Myeloma & Leukemia|April 20, 2025
Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Dynamic Features of Disease ProgressionLuis E Aguirre, Somedeb Ball, Akriti Jain, et al.Clinical Lymphoma, Myeloma & Leukemia|June 27, 2022
CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid LeukemiaDasom Lee, Akriti G Jain, Yehuda Deutsch, et al.Clinical Lymphoma, Myeloma & Leukemia|August 9, 2023
Utilization of Serial Next-Generation Sequencing Among Patients Receiving CPX-351 for Newly Diagnosed Acute Myeloid LeukemiaAkriti G Jain, Somedeb Ball, Luis E Aguirre, et al.Haematologica|May 11, 2019
Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemiaChetasi Talati, Varun C Dhulipala, Mar Tine Extermann, et al.Annals of Hematology|September 7, 2024
Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemiaAkriti G Jain, Virginia O Volpe, Chen Wang, et al.Future Oncology (London, England)|March 7, 2026
POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinibPankit Vachhani, Abdulraheem Yacoub, Raajit Rampal, et al.Clinical Lymphoma, Myeloma & Leukemia|March 28, 2024
Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and OutcomesLuis E Aguirre, Akriti Jain, Somedeb Ball, et al.Annals of Hematology|April 18, 2024
Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CMLAkriti G Jain, Quinto Gesiotto, Somedeb Ball, et al.Leukemia Research|June 19, 2022
Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center databaseNoa Rippel, Douglas Tremblay, Nicole Zubizarreta, et al.Pageof 4